AU2019253023B2 - Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools - Google Patents

Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools Download PDF

Info

Publication number
AU2019253023B2
AU2019253023B2 AU2019253023A AU2019253023A AU2019253023B2 AU 2019253023 B2 AU2019253023 B2 AU 2019253023B2 AU 2019253023 A AU2019253023 A AU 2019253023A AU 2019253023 A AU2019253023 A AU 2019253023A AU 2019253023 B2 AU2019253023 B2 AU 2019253023B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
base
prodrug
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019253023A
Other languages
English (en)
Other versions
AU2019253023A1 (en
Inventor
Daniel DIPIETRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ucb Biosciences Inc
Original Assignee
Ucb Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biosciences Inc filed Critical Ucb Biosciences Inc
Publication of AU2019253023A1 publication Critical patent/AU2019253023A1/en
Assigned to ZOGENIX MDS, INC. reassignment ZOGENIX MDS, INC. Amend patent request/document other than specification (104) Assignors: MODIS THERAPEUTICS INC.
Assigned to ZOGENIX, INC. reassignment ZOGENIX, INC. Request for Assignment Assignors: ZOGENIX MDS, INC.
Assigned to UCB BIOSCIENCES, INC. reassignment UCB BIOSCIENCES, INC. Request for Assignment Assignors: ZOGENIX, INC.
Application granted granted Critical
Publication of AU2019253023B2 publication Critical patent/AU2019253023B2/en
Priority to AU2025201857A priority Critical patent/AU2025201857A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019253023A 2018-04-12 2019-04-12 Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools Active AU2019253023B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201857A AU2025201857A1 (en) 2018-04-12 2025-03-14 Prodrugs of deoxynucleosides for treatment of diseases caused by unbalanced nucleotide pools

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656861P 2018-04-12 2018-04-12
US62/656,861 2018-04-12
PCT/US2019/027364 WO2019200340A1 (en) 2018-04-12 2019-04-12 Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201857A Division AU2025201857A1 (en) 2018-04-12 2025-03-14 Prodrugs of deoxynucleosides for treatment of diseases caused by unbalanced nucleotide pools

Publications (2)

Publication Number Publication Date
AU2019253023A1 AU2019253023A1 (en) 2020-11-12
AU2019253023B2 true AU2019253023B2 (en) 2025-01-23

Family

ID=68163825

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019253023A Active AU2019253023B2 (en) 2018-04-12 2019-04-12 Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools
AU2025201857A Pending AU2025201857A1 (en) 2018-04-12 2025-03-14 Prodrugs of deoxynucleosides for treatment of diseases caused by unbalanced nucleotide pools

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201857A Pending AU2025201857A1 (en) 2018-04-12 2025-03-14 Prodrugs of deoxynucleosides for treatment of diseases caused by unbalanced nucleotide pools

Country Status (10)

Country Link
US (3) US11628182B2 (https=)
EP (1) EP3773603A4 (https=)
JP (2) JP7620781B2 (https=)
CN (1) CN112384228A (https=)
AU (2) AU2019253023B2 (https=)
BR (1) BR112020020804A2 (https=)
CA (1) CA3096264A1 (https=)
IL (1) IL277725B2 (https=)
MX (1) MX2020010667A (https=)
WO (1) WO2019200340A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11628182B2 (en) 2018-04-12 2023-04-18 Zogenix Mds, Inc. Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools
EP4313068A4 (en) * 2021-03-26 2024-12-25 UCB Biosciences, Inc. Aqueous solutions containing purines and pyrimidines and uses thereof
US20230000890A1 (en) * 2021-06-18 2023-01-05 Zogenix Mds, Inc. Prodrugs of Deoxynucleosides for Treatment of Mitochondrial Diseases Caused by Unbalanced Nucleotide Pools

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2017087517A1 (en) * 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Nucleic acid prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
EP0753525A4 (en) 1994-03-31 1997-09-03 Nippon Shinyaku Co Ltd CYCLIC NUCLEOTIDE DERIVATIVES
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
JP6599484B2 (ja) 2015-06-17 2019-10-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ミトコンドリアｄｎａ枯渇症候群を含む不均衡なヌクレオチドプールによって引き起こされる疾患のためのデオキシヌクレオシド療法
BR112018076913A2 (pt) 2016-06-24 2019-04-02 Emory University fosforamidatos para o tratamento do vírus da hepatite b
US11628182B2 (en) 2018-04-12 2023-04-18 Zogenix Mds, Inc. Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2017087517A1 (en) * 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Nucleic acid prodrugs

Also Published As

Publication number Publication date
EP3773603A1 (en) 2021-02-17
IL277725B2 (en) 2024-02-01
IL277725A (en) 2020-11-30
US20230181617A1 (en) 2023-06-15
WO2019200340A1 (en) 2019-10-17
JP7784411B2 (ja) 2025-12-11
US12419901B2 (en) 2025-09-23
US20210077519A1 (en) 2021-03-18
JP2021521210A (ja) 2021-08-26
JP2024038011A (ja) 2024-03-19
US11628182B2 (en) 2023-04-18
CN112384228A (zh) 2021-02-19
AU2019253023A1 (en) 2020-11-12
BR112020020804A2 (pt) 2021-01-12
MX2020010667A (es) 2021-01-08
JP7620781B2 (ja) 2025-01-24
IL277725B1 (en) 2023-10-01
US20230181616A1 (en) 2023-06-15
EP3773603A4 (en) 2022-03-30
AU2025201857A1 (en) 2025-04-03
CA3096264A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
AU2021250841B2 (en) Deoxynucleoside Therapy For Diseases Caused By Unbalanced Nucleotide Pools Including Mitochondrial DNA Depletion Syndromes
US12419901B2 (en) Prodrugs of deoxynucleosides for treatment of diseases caused by unbalanced nucleotide pools
US11633418B2 (en) Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
US20250049836A1 (en) Prodrugs of deoxynucleosides for treatment of mitochondrial diseases caused by unbalanced nucleotide pools
HK40020049A (en) Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ZOGENIX MDS, INC.

Free format text: FORMER NAME(S): MODIS THERAPEUTICS INC.

PC1 Assignment before grant (sect. 113)

Owner name: ZOGENIX, INC.

Free format text: FORMER APPLICANT(S): ZOGENIX MDS, INC.

PC1 Assignment before grant (sect. 113)

Owner name: UCB BIOSCIENCES, INC.

Free format text: FORMER APPLICANT(S): ZOGENIX, INC.

FGA Letters patent sealed or granted (standard patent)